Evidence map›Paper›PMID 41419974›Full record

ArticleJournal of nanobiotechnology2025

Entropy-driven signal amplification integrated with machine learning in multiplex lateral flow immunoassay for sensitive Point-of-Care colon cancer diagnosis.

Shiyu He, Lifan Gao, Ling Hu, Fuming Zhao, Tingting Liu, Yannan Chen, Yuping Liu, Yingchun Zuo, Chao Guo, Chenglin Li and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Shiyu HeJiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, 209 Tongshan Road, Xuzhou, 221004, Jiangsu, P. R. China.
Lifan GaoJiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, 209 Tongshan Road, Xuzhou, 221004, Jiangsu, P. R. China.
Ling HuHuashan Hospital, Fudan University, Shanghai, 200040, P. R. China.
Fuming ZhaoJiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, 209 Tongshan Road, Xuzhou, 221004, Jiangsu, P. R. China.
Tingting LiuJiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, 209 Tongshan Road, Xuzhou, 221004, Jiangsu, P. R. China.
Yannan ChenJiangsu Provincial Engineering Research Center for Medical Imaging and Digital Medicine, School of Medical Imaging, Xuzhou Medical University, Xuzhou, 221004, Jiangsu, P. R. China.
Yuping LiuJiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, 209 Tongshan Road, Xuzhou, 221004, Jiangsu, P. R. China.
Yingchun ZuoJiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, 209 Tongshan Road, Xuzhou, 221004, Jiangsu, P. R. China.
Chao GuoJiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, 209 Tongshan Road, Xuzhou, 221004, Jiangsu, P. R. China.
Chenglin LiJiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, 209 Tongshan Road, Xuzhou, 221004, Jiangsu, P. R. China.
Fenglei GaoJiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, 209 Tongshan Road, Xuzhou, 221004, Jiangsu, P. R. China.
Changyu WuJiangsu Provincial Engineering Research Center for Medical Imaging and Digital Medicine, School of Medical Imaging, Xuzhou Medical University, Xuzhou, 221004, Jiangsu, P. R. China. changyu.wu@xzhmu.edu.cn.
Shibao LiDepartment of Laboratory Medicine, Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221006, Jiangsu, P. R. China. sdjnshlb@xzhmu.edu.cn.
Yanyan YuJiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, 209 Tongshan Road, Xuzhou, 221004, Jiangsu, P. R. China. yyyxzmc@163.com.

Funding

Key Medical Talents of Xuzhou XWRCHT20220065National Key Research and Development Program of China 2024YFF1206803Science and Technology Planning Project of Xuzhou KC23307the Basic Research Program of Jiangsu BK20241772Xuzhou Medical University Affiliated Hospital Staff Study Abroad Special Fund XYFY202432
6 · The paper itself

Abstract

Investigations on epithelial-mesenchymal transition (EMT) events occurring on circulating tumor cells (CTCs) are poised to significantly advance nanoliquid biopsy methodologies. This study presented a colorimetric multiplex lateral flow immunoassay strip (mLFIA) for the simultaneous detection of EpCAM and Vimentin, two representative EMT biomarkers, on heterogeneous CTCs. The assay utilized an engineered magnetic probe (pCF-Apt-H1/H2), characterized by a zwitterionic polymer coating on Fe

Indexed as

Colonic NeoplasmsMachine LearningPoint-of-Care SystemsAptamers, NucleotideBiomarkers, TumorCell Line, TumorColorimetryEntropyEpithelial Cell Adhesion MoleculeEpithelial-Mesenchymal TransitionGoldHumansImmunoassayLimit of DetectionNeoplastic Cells, CirculatingVimentinAptamers, NucleotideBiomarkers, TumorEPCAM protein, humanEpithelial Cell Adhesion MoleculeGoldVimentinCTC based nanoliquid biospyEpithelial-mesenchymal transitionMachine learningMultiplex lateral flow immunoassayProtein biomarker

Identifiers

PMID41419974
PMCPMC12717704

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.